Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.

Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-1259. [Epub ahead of print]

PMID:
31371342
2.

Construct damage and loosening around glenoid implants: A longitudinal micro-CT study of five cadaver specimens.

Lewis GS, Brenza JB, Paul EM, Armstrong AD.

J Orthop Res. 2016 Jun;34(6):1053-60. doi: 10.1002/jor.23119. Epub 2015 Dec 28.

3.

A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA.

Mol Cancer Ther. 2015 Feb;14(2):461-9. doi: 10.1158/1535-7163.MCT-14-0431. Epub 2014 Dec 10.

4.

The roles of P2Y2 purinergic receptors in osteoblasts and mechanotransduction.

Xing Y, Gu Y, Bresnahan JJ, Paul EM, Donahue HJ, You J.

PLoS One. 2014 Sep 30;9(9):e108417. doi: 10.1371/journal.pone.0108417. eCollection 2014.

5.

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T.

J Thorac Oncol. 2013 Dec;8(12):1529-37. doi: 10.1097/JTO.0000000000000005.

6.

Patients' response toward an automated orthopedic osteoporosis intervention program.

Varacallo MA, Fox EJ, Paul EM, Hassenbein SE, Warlow PM.

Geriatr Orthop Surg Rehabil. 2013 Sep;4(3):89-98. doi: 10.1177/2151458513502039.

7.

Inhibition of GSK-3β rescues the impairments in bone formation and mechanical properties associated with fracture healing in osteoblast selective connexin 43 deficient mice.

Loiselle AE, Lloyd SA, Paul EM, Lewis GS, Donahue HJ.

PLoS One. 2013 Nov 8;8(11):e81399. doi: 10.1371/journal.pone.0081399. eCollection 2013.

8.

Interdependence of muscle atrophy and bone loss induced by mechanical unloading.

Lloyd SA, Lang CH, Zhang Y, Paul EM, Laufenberg LJ, Lewis GS, Donahue HJ.

J Bone Miner Res. 2014;29(5):1118-30. doi: 10.1002/jbmr.2113.

9.

Specific biomimetic hydroxyapatite nanotopographies enhance osteoblastic differentiation and bone graft osteointegration.

Loiselle AE, Wei L, Faryad M, Paul EM, Lewis GS, Gao J, Lakhtakia A, Donahue HJ.

Tissue Eng Part A. 2013 Aug;19(15-16):1704-12. doi: 10.1089/ten.TEA.2012.0560. Epub 2013 Apr 25.

10.

Osteoblast and osteocyte-specific loss of Connexin43 results in delayed bone formation and healing during murine fracture healing.

Loiselle AE, Paul EM, Lewis GS, Donahue HJ.

J Orthop Res. 2013 Jan;31(1):147-54. doi: 10.1002/jor.22178. Epub 2012 Jun 20.

11.

Connexin 43 deficiency attenuates loss of trabecular bone and prevents suppression of cortical bone formation during unloading.

Lloyd SA, Lewis GS, Zhang Y, Paul EM, Donahue HJ.

J Bone Miner Res. 2012 Nov;27(11):2359-72. doi: 10.1002/jbmr.1687.

12.

Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone.

Zhang Y, Paul EM, Sathyendra V, Davison A, Sharkey N, Bronson S, Srinivasan S, Gross TS, Donahue HJ.

PLoS One. 2011;6(8):e23516. doi: 10.1371/journal.pone.0023516. Epub 2011 Aug 29.

13.

Endoscopic basilic vein transposition for hemodialysis access.

Paul EM, Sideman MJ, Rhoden DH, Jennings WC.

J Vasc Surg. 2010 Jun;51(6):1451-6. doi: 10.1016/j.jvs.2009.12.062. Epub 2010 Mar 20.

14.

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation.

Gomes RR Jr, Buttke P, Paul EM, Sikes RA.

Clin Exp Metastasis. 2009;26(7):641-51. doi: 10.1007/s10585-009-9263-x. Epub 2009 May 7.

PMID:
19421879
15.

Validation of three-dimensional models of in situ scapulae.

Bryce CD, Pennypacker JL, Kulkarni N, Paul EM, Hollenbeak CS, Mosher TJ, Armstrong AD.

J Shoulder Elbow Surg. 2008 Sep-Oct;17(5):825-32. doi: 10.1016/j.jse.2008.01.141. Epub 2008 May 19.

PMID:
18490182
16.

Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.

Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC.

J Clin Invest. 2008 May;118(5):1858-66. doi: 10.1172/JCI34257.

17.

Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.

Stephan C, Meyer HA, Paul EM, Kristiansen G, Loening SA, Lein M, Jung K.

Anticancer Res. 2007 Jul-Aug;27(4A):1833-6.

18.

A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH.

Clin Cancer Res. 2007 Jun 1;13(11):3276-85.

19.

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.

Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB Jr, Verweij J.

Cancer Chemother Pharmacol. 2005 Jan;55(1):91-9. Epub 2004 Jul 28.

PMID:
15565444
20.

Short-term outcome analysis of total pelvic reconstruction with mesh: the vaginal approach.

Shah DK, Paul EM, Rastinehad AR, Eisenberg ER, Badlani GH.

J Urol. 2004 Jan;171(1):261-3.

PMID:
14665889
21.

Choosing the ideal nephrostomy tube.

Paul EM, Marcovich R, Lee BR, Smith AD.

BJU Int. 2003 Nov;92(7):672-7. Review. No abstract available.

22.
23.

11-year outcome analysis of endourethral prosthesis for the treatment of recurrent bulbar urethral stricture.

Shah DK, Paul EM, Badlani GH; North American Study Group.

J Urol. 2003 Oct;170(4 Pt 1):1255-8.

PMID:
14501736
24.

Broad based tension-free synthetic sling for stress urinary incontinence: 5-year outcome.

Shah DK, Paul EM, Amukele S, Eisenberg ER, Badlani GH.

J Urol. 2003 Sep;170(3):849-51.

PMID:
12913714
25.

False fracture of the penis.

Shah DK, Paul EM, Meyersfield SA, Schoor RA.

Urology. 2003 Jun;61(6):1259.

PMID:
12809921
26.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH.

J Clin Oncol. 2002 Jul 1;20(13):2943-50.

PMID:
12089223
27.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.

Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH.

Br J Cancer. 2001 Jan 5;84(1):42-7.

28.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J.

Anticancer Drugs. 1999 Sep;10(8):719-28.

PMID:
10573204
29.

Comparison of fixation methods for preventing pelvic ring expansion.

Vrahas MS, Wilson SC, Cummings PD, Paul EM.

Orthopedics. 1998 Mar;21(3):285-9.

PMID:
9547813
30.

Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody.

Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, Carrasco N.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5568-73.

31.

A simple method to measure compartment pressures using an intravenous catheter.

Wilson SC, Vrahas MS, Berson L, Paul EM.

Orthopedics. 1997 May;20(5):403-6.

PMID:
9172247
32.

The effectiveness of the cervical halo: open versus closed ring. A preliminary report.

Wetzel FT, Dunsieth NW Jr, Kuhlengel KR, Paul EM, Lahey DM.

Paraplegia. 1995 Feb;33(2):110-5.

33.

Localization of an embolized catheter tip by digital image enhancement.

Wilson SC, Paul EM, Channin DS, Segal LS.

AJR Am J Roentgenol. 1994 Nov;163(5):1230-2. No abstract available.

PMID:
7976907
35.

Field performance of derived generations of transgenic tobacco.

Caligari PD, Yapabandara YM, Paul EM, Perret J, Roger P, Dunwell JM.

Theor Appl Genet. 1993 Aug;86(7):875-9. doi: 10.1007/BF00212615.

PMID:
24193884
36.
37.

[Avoidable deaths in the evaluation of the performance of health services. II. European Atlas of avoidable deaths: initial data and several reflections].

Morosini PL, Lauriola P, Magliola E, Feola G, Paul EM.

Epidemiol Prev. 1990 Dec;12(45):48-58. Italian.

PMID:
2151327
39.
40.

Amniotic fluid alpha-fetoprotein measurements by laser immunonephelometry.

Shulman G, Paul EM, Demers LM.

Clin Chim Acta. 1980 Nov 20;108(1):151-6.

PMID:
6160929
41.

Cost containment in laser immunonephelometry.

Shulman G, Paul EM.

Clin Biochem. 1980 Aug;13(4):171-6. No abstract available.

PMID:
6778633

Supplemental Content

Support Center